-
Baekje Shenzhou: Phase 3 RATIONALE 315 trial of tirelizumab combined with chemotherapy for resectable NSCLC achieved its primary endpoint of MPR and EFS
On October 22nd, the Baekje Shenzhou official announced that the Phase 3 clinical trial of Tirelizumab combined with chemotherapy for resectable NSCLC achieved its primary endpoints of MPR and EFS in ... -
Baekje Shenzhou Zebtinib ALPINE Research Appears 2023 ASH Latest Follow up Data shows Continuous Benefits
From December 9th to 11th, as one of the largest academic events in the world of hematology, the American Society of Hematology (ASH) Annual Conference was successfully held. During this conference, ... -
Baekje Shenzhou Hong Kong stock fell more than 5%
On the morning of December 21st, the Hong Kong stock of Baekje Shenzhou fell more than 5%, while the A-share of Baekje Shenzhou is now down 2%. -
Baekje Shenzhou Tirelizumab has been approved for marketing by the FDA
On March 15th, Baekje announced that the US Food and Drug Administration (FDA) has approved tirizumab as a monotherapy for adult patients with unresectable or metastatic esophageal squamous cell carc ... -
BeiGene: Tirelizumab Approved for Market by FDA
On March 15th, Securities Daily News reported that BeiGene announced that the company has recently learned that the US Food and Drug Administration (FDA) has approved the company's core product, Tera ... -
BeiGene: First quarter loss of 1.908 billion yuan
Securities Times e-Company News: BeiGene (688235) disclosed its first quarter report on the evening of May 10, stating that it achieved a revenue of 5.359 billion yuan in the first quarter of 2024, a ...